Carboplatin plus Paclitaxel Therapy after Docetaxel in Men with Metastatic Castrate Resistant Prostate Cancer published a dual-center study today that confirms that carboplatin and paclitaxel (a taxane product) has an active effect on PSA when used in the treatment of men with castrate resistant prostate cancer (CRPC) after docetaxel (chemotherapy for prostate cancer). […]